Trial Profile

A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 23 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary) ; Diphenhydramine; Methylprednisolone; Paracetamol; Tacrolimus
Indications Membranous glomerulonephritis
Focus Registrational; Therapeutic Use
Acronyms MAJESTY
Sponsors Roche

Most Recent Events

16 Feb 2026 Results presented at Roche media release.
16 Feb 2026 According to Genentech Media Release, data will be presented at an upcoming medical meeting and shared with health authorities including the U.S. Food and Drug Administration and the European Medicines Agency.
16 Feb 2026 According to Genentech Media Release, Primary endpoint (Percentage of Participants who Achieve a Complete Remission (CR) at Week 104) has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com